- Home
- Publications
- Publication Search
- Publication Details
Title
A Review of Drug Therapy in Vestibular Schwannoma
Authors
Keywords
-
Journal
Drug Design Development and Therapy
Volume Volume 15, Issue -, Pages 75-85
Publisher
Informa UK Limited
Online
2021-01-08
DOI
10.2147/dddt.s280069
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Bevacizumab for NF2‐associated vestibular schwannomas of childhood and adolescence
- (2020) Samuele Renzi et al. PEDIATRIC BLOOD & CANCER
- Author Correction: A VEGF receptor vaccine demonstrates preliminary efficacy in neurofibromatosis type 2
- (2020) Ryota Tamura et al. Nature Communications
- Ponatinib: a novel multi-tyrosine kinase inhibitor against human malignancies
- (2019) Fiona H Tan et al. OncoTargets and Therapy
- Sustained imaging response and hearing preservation with low-dose bevacizumab in sporadic vestibular schwannoma
- (2019) Matthias A Karajannis et al. NEURO-ONCOLOGY
- COX2 expression is associated with proliferation and tumor extension in vestibular schwannoma but is not influenced by acetylsalicylic acid intake
- (2019) Felix Behling et al. Acta Neuropathologica Communications
- [68Ga]-Pentixafor PET/CT for CXCR4-Mediated Imaging of Vestibular Schwannomas
- (2019) Maria Breun et al. Frontiers in Oncology
- Minimal Effect of Bevacizumab Treatment on Residual Vestibular Schwannomas after Partial Resection in Young Neurofibromatosis Type 2 Patients
- (2019) Isabel Gugel et al. Cancers
- Multicenter, Prospective, Phase II and Biomarker Study of High-Dose Bevacizumab as Induction Therapy in Patients With Neurofibromatosis Type 2 and Progressive Vestibular Schwannoma
- (2019) Scott R. Plotkin et al. JOURNAL OF CLINICAL ONCOLOGY
- Activation of the HGF/c-Met axis in the tumor microenvironment: A multispecies model
- (2018) Anna Konstorum et al. JOURNAL OF THEORETICAL BIOLOGY
- Aspirin does not prevent growth of vestibular schwannomas: A case-control study
- (2018) Samuel MacKeith et al. LARYNGOSCOPE
- Ailanthone Promotes Human Vestibular Schwannoma Cell Apoptosis and Autophagy by Downregulation of miR-21
- (2018) Peizhen Yang et al. ONCOLOGY RESEARCH
- Targeting the cMET pathway augments radiation response without adverse effect on hearing in NF2 schwannoma models
- (2018) Yingchao Zhao et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- CXCR4: A new player in vestibular schwannoma pathogenesis
- (2018) Maria Breun et al. Oncotarget
- A proteasome-resistant fragment of NIK mediates oncogenic NF-κB signaling in schwannomas
- (2018) Jeffrey R Gehlhausen et al. HUMAN MOLECULAR GENETICS
- Progression of hearing loss after LINAC-based stereotactic radiotherapy for vestibular schwannoma is associated with cochlear dose, not with pre-treatment hearing level
- (2018) A. van Linge et al. Radiation Oncology
- Publisher Correction: Computational repositioning and preclinical validation of mifepristone for human vestibular schwannoma
- (2018) Jessica E. Sagers et al. Scientific Reports
- Combination Therapy with c-Met and Src Inhibitors Induces Caspase-Dependent Apoptosis of Merlin-Deficient Schwann Cells and Suppresses Growth of Schwannoma Cells
- (2017) Marisa A. Fuse et al. MOLECULAR CANCER THERAPEUTICS
- LiCl Treatment Induces Programmed Cell Death of Schwannoma Cells through AKT- and MTOR-Mediated Necroptosis
- (2017) Ying Wang et al. NEUROCHEMICAL RESEARCH
- Congress of Neurological Surgeons Systematic Review and Evidence-Based Guidelines on Emerging Therapies for the Treatment of Patients With Vestibular Schwannomas
- (2017) Jamie J Van Gompel et al. NEUROSURGERY
- Vestibular Schwannoma Growth With Aspirin and Other Nonsteroidal Anti-inflammatory Drugs
- (2017) Jacob B. Hunter et al. OTOLOGY & NEUROTOLOGY
- Chemopreventative celecoxib fails to prevent schwannoma formation or sensorineural hearing loss in genetically engineered murine model of neurofibromatosis type 2
- (2017) Benjamin M. Wahle et al. Oncotarget
- Ponatinib promotes a G1 cell-cycle arrest of merlin/NF2-deficient human schwann cells
- (2017) Alejandra M. Petrilli et al. Oncotarget
- Tumor-Penetrating Delivery of siRNA against TNFα to Human Vestibular Schwannomas
- (2017) Yin Ren et al. Scientific Reports
- Short-Term Clinico-Radiographic Response to Super-Selective Intra-Arterial Cerebral Infusion of Bevacizumab for the Treatment of Vestibular Schwannomas in Neurofibromatosis Type 2
- (2017) H.A. Riina et al. INTERVENTIONAL NEURORADIOLOGY
- Mechanism-based modeling of the clinical effects of bevacizumab and everolimus on vestibular schwannomas of patients with neurofibromatosis type 2
- (2016) Aziz Ouerdani et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Activation of the c-Met Pathway Mobilizes an Inflammatory Network in the Brain Microenvironment to Promote Brain Metastasis of Breast Cancer
- (2016) F. Xing et al. CANCER RESEARCH
- YAP Mediates Tumorigenesis in Neurofibromatosis Type 2 by Promoting Cell Survival and Proliferation through a COX-2-EGFR Signaling Axis
- (2016) W. Guerrant et al. CANCER RESEARCH
- CXCR4 signaling in health and disease
- (2016) Tommaso Pozzobon et al. IMMUNOLOGY LETTERS
- Efficacy and Biomarker Study of Bevacizumab for Hearing Loss Resulting From Neurofibromatosis Type 2–Associated Vestibular Schwannomas
- (2016) Jaishri O. Blakeley et al. JOURNAL OF CLINICAL ONCOLOGY
- Surgical salvage of recurrent vestibular schwannoma following prior stereotactic radiosurgery
- (2016) Stephanie C. Wise et al. LARYNGOSCOPE
- Crizotinib inhibits NF2-associated schwannoma through inhibition of focal adhesion kinase 1
- (2016) Scott Troutman et al. Oncotarget
- Interplay between VEGF-A and cMET signaling in human vestibular schwannomas and schwann cells
- (2015) Sonam Dilwali et al. CANCER BIOLOGY & THERAPY
- Reduced dosage of bevacizumab in treatment of vestibular schwannomas in patients with neurofibromatosis type 2
- (2015) Said Farschtschi et al. EUROPEAN ARCHIVES OF OTO-RHINO-LARYNGOLOGY
- Bevacizumab decreases vestibular schwannomas growth rate in children and teenagers with neurofibromatosis type 2
- (2015) Audrey Hochart et al. JOURNAL OF NEURO-ONCOLOGY
- Phase II study of mTORC1 inhibition by everolimus in neurofibromatosis type 2 patients with growing vestibular schwannomas
- (2015) Stéphane Goutagny et al. JOURNAL OF NEURO-ONCOLOGY
- Tanshinone IIA exerts antitumor activity against vestibular schwannoma cells by inhibiting the expression of hypoxia-inducible factor-1α
- (2015) JU YEON KIM et al. Molecular Medicine Reports
- Preclinical validation of anti-nuclear factor-kappa B therapy to inhibit human vestibular schwannoma growth
- (2015) Sonam Dilwali et al. Molecular Oncology
- Anti-VEGF treatment improves neurological function and augments radiation response in NF2 schwannoma model
- (2015) Xing Gao et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Nonsteroidal anti-inflammatory medications are cytostatic against human vestibular schwannomas
- (2015) Sonam Dilwali et al. Translational Research
- Immunohistochemical profile of cytokines and growth factors expressed in vestibular schwannoma and in normal vestibular nerve tissue
- (2015) SAMANTA TAURONE et al. Molecular Medicine Reports
- Merlin-Deficient Human Tumors Show Loss of Contact Inhibition and Activation of Wnt/β-Catenin Signaling Linked to the PDGFR/Src and Rac/PAK Pathways
- (2015) Lu Zhou et al. NEOPLASIA
- Merlin/NF2 Loss-Driven Tumorigenesis Linked to CRL4DCAF1-Mediated Inhibition of the Hippo Pathway Kinases Lats1 and 2 in the Nucleus
- (2014) Wei Li et al. CANCER CELL
- Long-term toxicity of bevacizumab therapy in neurofibromatosis 2 patients
- (2014) Katherine M. Slusarz et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- The effect of bevacizumab on vestibular schwannoma tumour size and hearing in patients with neurofibromatosis type 2
- (2014) Mikkel Christian Alanin et al. EUROPEAN ARCHIVES OF OTO-RHINO-LARYNGOLOGY
- Double-Blind, Placebo-Controlled, Multicenter, Randomized, Phase IIB Neoadjuvant Study of Letrozole-Lapatinib in Postmenopausal Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative, Operable Breast Cancer
- (2014) Valentina Guarneri et al. JOURNAL OF CLINICAL ONCOLOGY
- mTORC1 inhibition delays growth of neurofibromatosis type 2 schwannoma
- (2014) Marco Giovannini et al. NEURO-ONCOLOGY
- Aspirin Intake Correlates With Halted Growth of Sporadic Vestibular Schwannoma In Vivo
- (2014) Cherian K. Kandathil et al. OTOLOGY & NEUROTOLOGY
- c-Met signaling in the development of tumorigenesis and chemoresistance: Potential applications in pancreatic cancer
- (2014) Daniel Delitto WORLD JOURNAL OF GASTROENTEROLOGY
- Review of radiation therapy services for neurofibromatosis (NF2) patients in England
- (2013) Catherine E. Gilkes et al. BRITISH JOURNAL OF NEUROSURGERY
- Phase II study of everolimus in children and adults with neurofibromatosis type 2 and progressive vestibular schwannomas
- (2013) Matthias A. Karajannis et al. NEURO-ONCOLOGY
- Sporadic Vestibular Schwannomas Associated With Good Hearing Secrete Higher Levels of Fibroblast Growth Factor 2 Than Those Associated With Poor Hearing Irrespective of Tumor Size
- (2013) Sonam Dilwali et al. OTOLOGY & NEUROTOLOGY
- Natural Compounds as Potential Treatments of NF2-Deficient Schwannoma and Meningioma
- (2013) Samuel A. Spear et al. OTOLOGY & NEUROTOLOGY
- Merlin, the NF2 Gene Product
- (2013) Nives Pećina-Šlaus PATHOLOGY & ONCOLOGY RESEARCH
- Assessment of antiangiogenic effect of imatinib mesylate on vestibular schwannoma tumors using in vivo corneal angiogenesis assay
- (2012) Ulaş Yener et al. JOURNAL OF NEUROSURGERY
- Regulation of mTOR Complex 2 Signaling in Neurofibromatosis 2-Deficient Target Cell Types
- (2012) M. F. James et al. MOLECULAR CANCER RESEARCH
- Phase II trial of lapatinib in adult and pediatric patients with neurofibromatosis type 2 and progressive vestibular schwannomas
- (2012) Matthias A. Karajannis et al. NEURO-ONCOLOGY
- Treatment of Vestibular Schwannoma Cells With ErbB Inhibitors
- (2012) Matthew L. Bush et al. OTOLOGY & NEUROTOLOGY
- Bevacizumab for Progressive Vestibular Schwannoma in Neurofibromatosis Type 2
- (2012) Scott R. Plotkin et al. OTOLOGY & NEUROTOLOGY
- Genetic and Epigenetic Alterations of the NF2 Gene in Sporadic Vestibular Schwannomas
- (2012) Jong Dae Lee et al. PLoS One
- Investigation of the In Vitro Therapeutic Efficacy of Nilotinib in Immortalized Human NF2-Null Vestibular Schwannoma Cells
- (2012) Nesrin Sabha et al. PLoS One
- Multifaceted roles of PGE2 in inflammation and cancer
- (2012) Masako Nakanishi et al. Seminars in Immunopathology
- Clinical features of intracranial vestibular schwannomas
- (2012) XIANG HUANG et al. Oncology Letters
- A Tight Junction-Associated Merlin-Angiomotin Complex Mediates Merlin's Regulation of Mitogenic Signaling and Tumor Suppressive Functions
- (2011) Chunling Yi et al. CANCER CELL
- MET inhibition in tumor cells by PHA665752 impairs homologous recombination repair of DNA double strand breaks
- (2011) Michaela Medová et al. INTERNATIONAL JOURNAL OF CANCER
- Preclinical validation of AR42, a novel histone deacetylase inhibitor, as treatment for vestibular schwannomas
- (2011) Abraham Jacob et al. LARYNGOSCOPE
- Nilotinib alone or in combination with selumetinib is a drug candidate for neurofibromatosis type 2
- (2011) S. Ammoun et al. NEURO-ONCOLOGY
- AR42, a novel histone deacetylase inhibitor, as a potential therapy for vestibular schwannomas and meningiomas
- (2011) M. L. Bush et al. NEURO-ONCOLOGY
- Tumor pseudoprogression following radiosurgery for vestibular schwannoma
- (2011) C. Hayhurst et al. NEURO-ONCOLOGY
- Cyclooxygenase-2 Supports Tumor Proliferation in Vestibular Schwannomas
- (2011) Bujung Hong et al. NEUROSURGERY
- ErbB Expression, Activation, and Inhibition With Lapatinib and Tyrphostin (AG825) in Human Vestibular Schwannomas
- (2011) Zana K. Ahmad et al. OTOLOGY & NEUROTOLOGY
- Transcriptional and posttranslational up-regulation of HER3 (ErbB3) compensates for inhibition of the HER2 tyrosine kinase
- (2011) J. T. Garrett et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Anti–Vascular Endothelial Growth Factor Therapies as a Novel Therapeutic Approach to Treating Neurofibromatosis-Related Tumors
- (2010) Hon Kit Wong et al. CANCER RESEARCH
- ErbB/HER receptor activation and preclinical efficacy of lapatinib in vestibular schwannoma
- (2010) S. Ammoun et al. NEURO-ONCOLOGY
- Erlotinib for Progressive Vestibular Schwannoma in Neurofibromatosis 2 Patients
- (2010) Scott R. Plotkin et al. OTOLOGY & NEUROTOLOGY
- Potential Role of Imatinib Mesylate (Gleevec, STI-571) in the Treatment of Vestibular Schwannoma
- (2010) Xabier Altuna et al. OTOLOGY & NEUROTOLOGY
- EGF and bFGF Promote Invasion That Is Modulated by PI3/Akt Kinase and Erk in Vestibular Schwannoma
- (2010) Katherine J. Blair et al. OTOLOGY & NEUROTOLOGY
- Hepatocyte growth factor protects endothelial cells against gamma ray irradiation-induced damage
- (2009) Shun-ying Hu et al. ACTA PHARMACOLOGICA SINICA
- Human Schwannomas Express Activated Platelet-Derived Growth Factor Receptors and c-kit and Are Growth Inhibited by Gleevec (Imatinib Mesylate)
- (2009) J. Mukherjee et al. CANCER RESEARCH
- Akt Phosphorylation of Merlin Enhances Its Binding to Phosphatidylinositols and Inhibits the Tumor-Suppressive Activities of Merlin
- (2009) M. Okada et al. CANCER RESEARCH
- mTOR Inhibitor RAD001 (Everolimus) Has Antiangiogenic/Vascular Properties Distinct from a VEGFR Tyrosine Kinase Inhibitor
- (2009) H. A. Lane et al. CLINICAL CANCER RESEARCH
- Clinical Pharmacokinetics of the BCR–ABL Tyrosine Kinase Inhibitor Nilotinib
- (2009) C Tanaka et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Growth inhibitory and anti-tumour activities of OSU-03012, a novel PDK-1 inhibitor, on vestibular schwannoma and malignant schwannoma cells
- (2009) Tina X. Lee et al. EUROPEAN JOURNAL OF CANCER
- Vestibular schwannoma: role of conservative management
- (2009) R Suryanarayanan et al. JOURNAL OF LARYNGOLOGY AND OTOLOGY
- Neurofibromatosis type 2
- (2009) Ashok R Asthagiri et al. LANCET
- Hearing Improvement after Bevacizumab in Patients with Neurofibromatosis Type 2
- (2009) Scott R. Plotkin et al. NEW ENGLAND JOURNAL OF MEDICINE
- ErbB and Nrg
- (2009) Joni K. Doherty et al. OTOLOGY & NEUROTOLOGY
- Phosphatidylinositol 3-Kinase/AKT Pathway Activation in Human Vestibular Schwannoma
- (2009) Abraham Jacob et al. OTOLOGY & NEUROTOLOGY
- Semaphorin 3A suppresses VEGF-mediated angiogenesis yet acts as a vascular permeability factor
- (2008) L. M. Acevedo et al. BLOOD
- Targeting the PI3K/Akt/mTOR pathway: Effective combinations and clinical considerations
- (2008) J LOPICCOLO et al. DRUG RESISTANCE UPDATES
- The ErbB Inhibitors Trastuzumab and Erlotinib Inhibit Growth of Vestibular Schwannoma Xenografts in Nude Mice
- (2008) J. Jason Clark et al. OTOLOGY & NEUROTOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started